Navigation Links
ARIUS Announces Third Quarter Fiscal 2007 Financial Results
Date:10/12/2007

and administrative expenses, and lower interest income, offset partially by lower interest expense and higher revenues.

Revenue decreased to $845,974 for the nine-month period ended August 31, 2007, compared to $2,668,010 for the nine-month period ended August 31, 2006. The decrease during the nine-month period ended August 31, 2007, was primarily the result of the recognition of licensing fee revenue from Genentech in the fiscal 2006 period, partially offset by the recognition of revenue from the Takeda collaboration and the recognition of unearned revenue from PDL BioPharma Inc. ("PDL"). For the three-month period ended August 31, 2007, the Company's revenue increased to $716,128 compared to $226,710 for the three-month period ended August 31, 2006. The increase in the three month period relates to the recognition of revenue from the Takeda collaboration and the recognition of unearned revenue from PDL in the fiscal 2007 period.

Interest income increased to $537,128 for the nine-month period ended August 31, 2007, compared to $396,966 for the same period in fiscal 2006. For the three-month period ended August 31, 2007, the Company's interest income decreased to $155,721 compared to $275,529 for the same period in fiscal 2006. The increase for the nine-month period was primarily the result of higher average cash balances due to the completion of a private placement in February and March 2006, payments from the Genentech licensing agreement and the Takeda research collaboration and higher interest rates. The decrease for the three-month period was primarily the result of lower average cash and investment balances.

Research and development costs amounted to $6,461,991 for the nine-month period ended August 31, 2007, compared to $3,175,663 for the same period in fiscal 2006. For the three-month period ended August 31, 2007, the Company's research and development costs amounted to $2,402,060 compared to $1,303,088 for the same period in fiscal 2006. T
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Streptococcus salivarius
2. Streptococcus salivarius
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... - The 53 Wisconsin companies that won more ... Research (SBIR) and Small Business Technology Transfer (STTR) awards ... an upcoming banquet in Madison. , ,The awards banquet ... workshop. The workshop will focus on SBIR/STTR funding opportunities. ...
... Bend, Wis. - Serigraph Inc. will manufacture, ... tags through a licensing agreement with MIKOH Corp. ... tag if it is interfered with after its original positioning, ... from one item to another without affecting the function of ...
... is the biotech industry to the economy of a region? ... , ,Better yet, look at the numbers. , ,That's what ... Milken Institute , did for a landmark study released ... in Philadelphia. Philly leaders wanted to know where that city ...
Cached Biology Technology:Better collaboration urged to further Wisconsin biotech 2
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... completing the sequencing of the chimpanzee genome last year, geneticists ... of our closest evolutionary relative, looking for the differences that ... found the human DNA sequence with the most dramatically increased ... DNA is still unknown, but it appears to be directly ...
... has become a worldwide health problem, affecting millions ... Researchers are experimenting with combinations of anti-inflammatory medicines ... research presented today at Digestive Disease Week® 2006 ... progress to improve symptoms of the disease. ...
... the University of Colorado-Denver and Health Sciences Center and ... how cells respond to DNA damage and other acute ... which could lead to new diagnostic markers and cancer ... reports in the May 21 advanced online version of ...
Cached Biology News:Researchers identify human DNA on the fast track 2Researchers identify human DNA on the fast track 3Novel therapy combinations gain ground in treating hepatitis 2Novel therapy combinations gain ground in treating hepatitis 3Novel therapy combinations gain ground in treating hepatitis 4Novel therapy combinations gain ground in treating hepatitis 5Novel therapy combinations gain ground in treating hepatitis 6Researchers uncover new mechanism of tumor suppressor 2
Antibody Diluent for IHC 125 ml...
QPRT Antibody...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
Biology Products: